Novo Nordisk Pharmatech enters distribution agreement with Azelis for pharmaceutical grade quaternary ammonium compounds
Novo Nordisk Pharmatech has entered into an agreement with global speciality chemicals distributor, Azelis, for the distribution of pharmaceutical grade quaternary ammonium compounds (quats).
Distrubution will cover to the pharmaceutical and medical device markets in Germany, Spain Portugal, UK and Ireland.
Quats are positively-charged surface agents (surfactants). They bind to negatively-charged membranes to destroy bacteria, viruses, moulds and fungi.
Our pharma experts see potential new applications in the growing wound care market.
Matthew Dickman, Market Segment Director Pharma Azelis said: “Novo Nordisk Pharmatech is the industry leader in pharmaceutical-grade quats. They compliment an existing Azelis portfolio of pharma antimicrobials.”
“Alongside established uses of quats, our pharma experts see potential new applications in the growing wound care market.”
“Our local teams, who work with customers to support both their current and NPD requirements, will be investigating these options in the coming period.”
Novo Nordisk Pharmatech manufactures its quats (Benzalkonium, Cetrimide and Cetyl Trimethyl Ammonium Bromide, including customised grades) to the highest (c)GMP standards.
The company's site in Koge, Denmark, is audited by the Danish Medicines Agency and US Food and Drug Administration (FDA).
Products comply with the latest major pharmacopoeia and are supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.